Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832600 | 0.87 | PTGER4 (0.81) | PTGER4KDM4ESRCPOLBALDH1A1 | |
| SCHEMBL29794143 | 0.87 | PTGER4 (0.81) | PTGER4KDM4ESRCPOLBALDH1A1 | |
| SCHEMBL21651446 | 0.86 | PTGER4 (0.73) | PTGER4KDM4EGRIK2GRIK1POLB | |
| SCHEMBL29493320 | 0.86 | PTGER4 (0.73) | PTGER4KDM4EGRIK2GRIK1POLB | |
| SCHEMBL28542163 | 0.86 | PTGER4 (0.74) | PTGER4KDM4EGRIK2GRIK1SRC | |
| SCHEMBL15396904 | 0.84 | PTGER4 (0.72) | PTGER4KDM4EMAOAMAOBHSD17B10 | |
| SCHEMBL15217969 | 0.84 | PTGER4 (0.72) | PTGER4KDM4EMAOAMAOBHSD17B10 | |
| SCHEMBL19214418 | 0.83 | PTGER4 (0.71) | PTGER4KDM4ENPSR1ALDH1A1CYP2A6 | |
| SCHEMBL12239095 | 0.80 | PTGER4 (0.67) | PTGER4KDM4EALDH1A1CYP2A6MEN1 | |
| SCHEMBL15774538 | 0.80 | PTGER4 (0.70) | PTGER4KDM4ESRCPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708311-B2 | Benzimidazole derivatives as EP4 antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9708311-B2 | Benzimidazole derivatives as EP4 antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9708311-B2 | Benzimidazole derivatives as EP4 antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-18 | — | — | US | disclosed |
| EP-2928884-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma AG (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| EP-2928884-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086739-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-12 | — | — | WO | disclosed |
| EP-1509518-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7176322-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1509518-A1 | CALCIUM RECEPTOR MODULATING AGENTS | Amgen, Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040077619-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003099814-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077619-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | PTGER4 365/4885KDM4E 3394/4885GRIK2 1286/4885 |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885KDM4E 1277/4885GRIK2 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.